Free Trial
NASDAQ:EYPT

Eyepoint Pharmaceuticals (EYPT) Stock Price, News & Analysis

Eyepoint Pharmaceuticals logo
$9.83 +0.17 (+1.80%)
Closing price 07/3/2025 02:34 PM Eastern
Extended Trading
$9.84 +0.00 (+0.01%)
As of 07/3/2025 04:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Eyepoint Pharmaceuticals Stock (NASDAQ:EYPT)

Key Stats

Today's Range
$9.63
$10.02
50-Day Range
$5.49
$10.54
52-Week Range
$3.91
$13.99
Volume
332,554 shs
Average Volume
815,241 shs
Market Capitalization
$676.69 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.67
Consensus Rating
Buy

Company Overview

Eyepoint Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
41st Percentile Overall Score

EYPT MarketRank™: 

Eyepoint Pharmaceuticals scored higher than 41% of companies evaluated by MarketBeat, and ranked 1963rd out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Eyepoint Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Eyepoint Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.

  • Read more about Eyepoint Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Eyepoint Pharmaceuticals are expected to decrease in the coming year, from ($2.13) to ($2.52) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Eyepoint Pharmaceuticals is -4.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Eyepoint Pharmaceuticals is -4.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Eyepoint Pharmaceuticals has a P/B Ratio of 1.99. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Eyepoint Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    10.25% of the float of Eyepoint Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Eyepoint Pharmaceuticals has a short interest ratio ("days to cover") of 8.1.
  • Change versus previous month

    Short interest in Eyepoint Pharmaceuticals has recently decreased by 6.00%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Eyepoint Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Eyepoint Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    10.25% of the float of Eyepoint Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Eyepoint Pharmaceuticals has a short interest ratio ("days to cover") of 8.1.
  • Change versus previous month

    Short interest in Eyepoint Pharmaceuticals has recently decreased by 6.00%, indicating that investor sentiment is improving significantly.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Eyepoint Pharmaceuticals this week, compared to 4 articles on an average week.
  • Search Interest

    6 people have searched for EYPT on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.
  • MarketBeat Follows

    8 people have added Eyepoint Pharmaceuticals to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Eyepoint Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 4.46% of the stock of Eyepoint Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    99.41% of the stock of Eyepoint Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Eyepoint Pharmaceuticals' insider trading history.
Receive EYPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eyepoint Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

EYPT Stock News Headlines

Breakout Rack: Momentum Stocks - This image is an original composition by MarketBeat using licensed and editorial elements. Not for redistribution or reuse.
Breakout Momentum Plays You May Not Know About
Momentum investing is all about timing—these three under-the-radar stocks have begun to rise by still seem to have room for further growth.
EYPT EyePoint Pharmaceuticals, Inc. - Seeking Alpha
Elon’s NEXT Big IPO?
Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it takes for the entire thing to burn right up. It’s a NEW internet service poised to disrupt the entire $3.2 trillion telecom industry. But you may only have this chance if you act before December 31st, 2025.
See More Headlines

EYPT Stock Analysis - Frequently Asked Questions

Eyepoint Pharmaceuticals' stock was trading at $7.45 on January 1st, 2025. Since then, EYPT shares have increased by 32.0% and is now trading at $9.8340.

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) posted its quarterly earnings results on Wednesday, May, 7th. The company reported ($0.65) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.65). The business had revenue of $24.50 million for the quarter, compared to analysts' expectations of $8.84 million. Eyepoint Pharmaceuticals had a negative trailing twelve-month return on equity of 54.27% and a negative net margin of 261.91%.
Read the conference call transcript
.

Eyepoint Pharmaceuticals shares reverse split before market open on Wednesday, December 9th 2020.The 1-10 reverse split was announced on Tuesday, December 8th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, December 9th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Shares of EYPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Eyepoint Pharmaceuticals investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), Meta Platforms (META), NVIDIA (NVDA), SPDR Dow Jones Industrial Average ETF Trust (DIA), Advanced Micro Devices (AMD) and Broadcom (AVGO).

Company Calendar

Last Earnings
5/07/2025
Today
7/04/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Measuring And Control Equipment
Current Symbol
NASDAQ:EYPT
Employees
120
Year Founded
1987

Price Target and Rating

Average Stock Price Target
$25.67
High Stock Price Target
$33.00
Low Stock Price Target
$15.00
Potential Upside/Downside
+161.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
9 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$130.87 million
Net Margins
-261.91%
Pretax Margin
-261.75%

Debt

Sales & Book Value

Annual Sales
$43.27 million
Price / Cash Flow
N/A
Book Value
$4.93 per share
Price / Book
1.99

Miscellaneous

Free Float
65,742,000
Market Cap
$676.68 million
Optionable
Optionable
Beta
1.67

Social Links

2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:EYPT) was last updated on 7/4/2025 by MarketBeat.com Staff
From Our Partners